PSA

What the prostate-specific antigen measures

Prostate-specific antigen (PSA) is an organ-specific, but not disease-specific, marker produced by both normal and malignant prostate tissue. Benign prostatic hyperplasia (BPH), prostatitis or other forms of inflammation or infection can also raise the serum level. An elevated PSA level therefore does not confirm the presence of cancer, and a level within the reference range does not definitively rule it out.

Why a single value does not provide a definitive threshold for cancer

There is no single PSA threshold that reliably distinguishes normal results from prostate cancer. A level above 4 ng/ml is often considered abnormal; for younger men, lower thresholds such as 2.5 ng/ml are sometimes used. These values are guidelines only; they do not constitute definitive proof of cancer nor do they automatically indicate the need for a biopsy.

The guidelines issued by the American Urological Association and the Society of Urologic Oncology (AUA/SUO) cite the following commonly used age-dependent reference ranges: 2.5 ng/ml for men in their 40s, 3.5 ng/ml for men in their 50s, 4.5 ng/ml for men in their 60s and 6.5 ng/ml for men in their 70s. The interpretation also depends on age, symptoms, clinical findings, individual risk, the laboratory and the measurement method.

What factors cause the value to shift temporarily

Infection, inflammation and a prostate biopsy can temporarily raise PSA levels. The National Cancer Institute (NCI) summary cites a possible effect lasting one to two months. Ejaculation and vigorous cycling are also listed as possible short-term influencing factors, although no standard correction factor has been established for these.

The AUA/SUO considers a digital rectal examination and cycling to be factors that do not significantly alter PSA levels in routine screening. Controlled ejaculation studies have predominantly shown no increase, or only a moderate increase of approximately 10 per cent. The findings therefore do not support a blanket 48-hour break prior to each sample collection.

A prospective intra-individual study involving 64 men aged between 49 and 79 found a rise in PSA levels in 87 per cent of participants following ejaculation. The mean relative increase was 41 per cent after one hour and 8 per cent after 24 hours; after 48 hours, 97 per cent had returned to their baseline levels. As the study did not have a parallel control group and primarily involved older men, its findings cannot be readily extrapolated to young strength athletes.

How finasteride affects interpretation

Finasteride reduces PSA levels by approximately 50 per cent in the first year. In the long-term data from the Prostate Cancer Prevention Trial, the required correction factor rose from 2 after 24 months to 2.5 after seven years. A time-independent rule of simply doubling each measured value therefore does not reflect this trend.

The data are predominantly from older men taking part in a prevention study. They cannot automatically be extrapolated to every dose, every duration of treatment, or to a combination with testosterone therapy or anabolic-androgenic steroids (AAS). The medication, duration of treatment and the actual findings must therefore be taken into account in the doctor’s interpretation.

What happens when a new, higher value is recorded

If the PSA level has risen again, the test should be repeated before any biomarkers, imaging or biopsy are carried out. The NCI summary suggests six to eight weeks as a possible timeframe for repeat testing; however, the AUA/SUO does not specify a general fixed timeframe. The timing depends on the clinical context.

A repeat test can help to contextualise a temporary increase, but does not automatically rule out a relevant medical condition. Symptoms, clinical findings, possible inflammation or infection, baseline values, age, individual risk and laboratory conditions may influence the decision on how to proceed. There is no evidence to support a standard time frame of four to six weeks for every elevated result.

Why PSA levels alone are not the deciding factor

The AUA/SUO recommends that PSA velocity should not be used as the sole basis for further diagnostic investigation. A single threshold value for the annual change should therefore not be the sole factor in determining the course of investigation.

A review of the evidence, comprising seven cross-sectional studies involving a total of 1,364 participants, examined the threshold of at least 0.75 ng/ml per year following a negative prostate biopsy. The 95 per cent confidence intervals ranged from a slight decrease to a slight increase in the probability of cancer; no clear added benefit was apparent. The quality of the evidence was low, and this specific population cannot be equated with young strength athletes.

Follow-up measurements can therefore continue to provide context, but neither a single measurement nor a specific rate of increase can replace the overall clinical assessment.

What can be inferred for strength athletes

The AUA/SUO recommends a baseline test for those at average risk aged between 45 and 50, and for those at increased risk as early as aged between 40 and 45. This recommendation relates to general early detection. No specific starting or threshold recommendation validated for anabolic-androgenic steroids (AAS) can be derived from this.

The guidelines and study data cited have not been validated for supraphysiological AAS cycles in strength athletes. It is therefore not possible to derive from them either a typical change in PSA under AAS or an AAS-specific testing interval or threshold value. General early detection and AAS use should not be tacitly equated.

When having a PSA test, you should disclose any medication you are taking, such as finasteride, any current symptoms, recent infections or surgical procedures, and the circumstances under which the test is being carried out. If the result is abnormal, further investigation should not be based on a single value or a self-calculated correction.

Classification

PSA is an organ-specific but not disease-specific marker. A meaningful assessment is not based on a single threshold value, but on the combined consideration of the measured value, age and risk, possible influencing factors, medication and confirmed repeat measurements. There is no reliable general rule regarding a universal threshold of 0.75 ng/ml per year, a 48-hour break from cycling, or a time-independent doubling of the finasteride dose.

This article was created using AI systems. Find out more